A1,
A2,
B,
C1,
C2,
D,
E,
F,
G-H,
I-K,
L,
M,
N,
O,
P1,
P2,
Q-R,
S,
T,
U-V,
W-Z
Overdose, Contraindications and Information - Pediatrace
Overdose, Contraindications and Information - Pediatrace
OVERDOSE
Single intravenous doses of 1 to 2 mg zinc/kg body weight have been given
to adult leukemic patients without toxic manifestations. However, acute
toxicity was reported in an adult when 10 mg zinc was infused over a period
of one hour on each of four consecutive days. Profuse sweating, decreased
level of consciousness, blurred vision, tachycardia (140/mm) and marked
hypothermia (94.2°F) on the fourth day were accompanied by a serum zinc
concentration of 207 mcg/mL. Symptoms abated within three hours. Hyperamylasemia
may be a sign of impending zinc overdosage; patients receiving an inadvertent
overdose (25 mg zinc/L of TPN solution, equivalent to 50 to 70 mg zinc/day)
developed hyperamylasemia (557 to 1850 Klein units; normal: 130 to 310).
Death resulted from an overdose in which 1683 mg zinc was delivered intravenously
over the course of 60 hours to a 72-year-old patient. Symptoms of zinc
toxicity included hypotension (80/40 mm Hg), pulmonary edema, diarrhea,
vomiting, jaundice and oliguria with a serum zinc level of 4184 mcg/100
mL. Calcium supplements may confer a protective effect against zinc toxicity.
Copper toxicity can produce prostration, behavior change, diarrhea, progressive
marasmus, hypotonia, photophobia and peripheral edema. Such symptoms have
been reported with a serum copper level of 286 mcg/100 mL. D-penicillamine
has been reported effective as an antidote.
Manganese toxicity in TPN patients has not been reported within the prescribed
dosage.
Trivalent chromium administered intravenously to TPN patients has been
shown to be nontoxic when given at dosage levels of up to 250 mcg/day
for two consecutive weeks.
Reported toxic reactions to chromium include nausea, vomiting, ulcers
of the gastrointestinal tract, renal and hepatic damage, convulsions and
coma. The acute LD50 for intravenous trivalent chromium in
rats was reported as 10 to 18 mg/kg.
CONTRAINDICATIONS
Pedtrace®-4 should not be given undiluted by direct injection into a
peripheral vein because of the potential of infusion phlebitis.
top
